Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLAUrious

Financiado

Cerrado

External Automatic Glaucoma Laser EAGLE for the first line glaucoma treatment...

External Automatic Glaucoma Laser EAGLE for the first line glaucoma treatment Commercial prototype development and validation The GLAUrious project is promoting the novel External Automatic Glaucoma Laser (EAGLE) device with the goal of providing accessible first-line treatment for glaucoma. Glaucoma, a chronic disease causing progressive optic nerve deg... ver más

29/02/2020

THE QUEEN'S UNIVER...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

THE QUEENS UNIVERSITY OF BELFAST No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-29

FTIPilot-1-2015: Fast Track to Innovation Pilot

I+D

Cerrada hace 9 años

0% 61% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

THE QUEEN'S UNIVERSITY OF BE...

261.79K€ | Lider

SOLUCIONES TECNICAS NOVOVENT...

M.C.I.

187.25K€ | Participante

UNIGE

264.68K€ | Participante

Proyectos interesantes

DPI2015-72948-EXP

Medical Technol...

Electronics

48K€ Cerrado

EyeAccess

Medical Technol...

Biomedical Imag...

7M€ Cerrado

Savesight

Medical Technol...

Environmental S...

71K€ Cerrado

DISEÑO Y DESARROLLO DE NUEVO IMPLANTE UVEOESC...

Medical Technol...

Medical Devices

276K€ Cerrado

PLEC2022-009214

Medical Technol...

Electronics

586K€ Cerrado

GALAHAD

Medical Technol...

Data Science

4M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 42 meses Fecha Inicio: 2016-08-25
Fecha Fin: 2020-02-29

Líder del proyecto

THE QUEENS UNIVERSITY OF BELFAST No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The GLAUrious project is promoting the novel External Automatic Glaucoma Laser (EAGLE) device with the goal of providing accessible first-line treatment for glaucoma. Glaucoma, a chronic disease causing progressive optic nerve degeneration, is the leading cause of irreversible blindness globally. Although incurable, disease progression is delayed by reducing intraocular pressure, thus preventing blindness. Some 64 million people worldwide suffer from glaucoma. Current first-line treatment requires daily eye drops, a strict regimen causing 50% patient dropout after 1 year. Laser treatment for glaucoma has been in use for many years. Its effect lasts for 2−5 years and is repeatable. This traditional 10-minute procedure, involving contact with the patient’s eye, requires the expertise of glaucoma specialists. Consequently, costs are high and accessibility to the general population is low. The novel EAGLE procedure is automated, non-invasive, non-contact, painless and user friendly—1 second of treatment by one press of a button. This revolutionary cost-effective device could be safely used by the world’s 212,000 ophthalmologists, thus becoming a primary treatment for glaucoma, overcoming serious problems of eye drop non-compliance and effectively preventing disease deterioration. GLAUrious project aims to ease commercialization of the EAGLE device by securing clinical prototype validation, streamlining commercial production, optimizing component costs, disseminating to key opinion leaders and distributors, and refining commercial strategy. Validation of EAGLE will allow its commercialization enabling penetration of the ophthalmic market and boosting of the industrial consortium partners (BEL and MCI). The multidisciplinary GLAUrious Consortium, with its four partners from three member states (Belgium, Italy, UK) and one associated state (Israel), incorporates two SMEs and two academic hospitals.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores